Overview
The Phase 3 pivotal study is designed to evaluate the efficacy and safety of RZ358 for the treatment of congenital hyperinsulinism (HI) as add-on to standard-of-care (SOC) therapy compared to SOC alone over 24 weeks and to evaluate the longer-term safety and efficacy of RZ358 during a subsequent open-label extension (OLE) period.
Description
Congenital hyperinsulinism (HI) is the most common cause of recurrent hypoglycemia in neonates and infants with an incidence of approximately 1 in 25,000 to 1 in 50,000 live births in the general population, and as high as 1 in 2,500 in certain populations with substantial consanguinity. Despite improved recognition, there is no satisfactory treatment or cure for congenital HI. Current medical therapies for congenital HI are directed at reducing or eliminating insulin production and/or secretion from the beta-cell. These current medications, however, achieve suboptimal glycemic control and/or have undesirable side effects. A therapy which safely and effectively attenuates the activity of insulin would address an important unmet need for these and other conditions associated with HI. This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled (SOC alone), parallel-arm, efficacy, and safety study of RZ358 in participants with congenital HI who have not achieved adequate hypoglycemia control with reasonable attempts at using usual SOC medical therapy. The study will randomize approximately 48 participants (≥1 year to ≤45 years of age) in a 1:1 ratio into 2 dosing arms (5 or 10 mg/kg with) and further randomize participants within each dosing level in a 2:1 ratio to receive RZ358 as add-on to SOC or placebo as add-on to SOC. An additional open-label (OL) arm will be conducted in parallel for participants who are ≥3 months to <1 year old (n=8), Upon completion of the pivotal treatment period (24-weeks), participants may roll-over to the OLE period at the discretion of the investigator and Sponsor.
Eligibility
Inclusion Criteria:
At screening, aged ≥ 3 months and ≤ 45 years old.
An established clinical diagnosis of congenital HI (hyperinsulinism), with or without
identification of a known monogenic variant by genetic testing.
Participant has failed to achieve adequate glycemic control with appropriate and reasonable
trials of locally accepted and available Standard of Care (SOC) medical therapies (e.g.,
diazoxide and somatostatin analogs (SSAs)) per the judgment of the investigator.
Experiencing ≥ 3 hypoglycemia events per week by screening Self-Monitoring Blood Glucose
(SMBG) and average daily percent time with hypoglycemia of ≥ 8% of the monitored screening
Continuous Glucose Monitor (CGM) time.
Exclusion Criteria:
Alanine aminotransaminase (ALT), aspartate aminotransaminase (AST), total bilirubin (TB),
alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) ≥ 1.5 × the upper limit of
normal for the age-specific reference range, regardless of assessed significance.
Body mass index (BMI) ≥ 35 kg/m2 for participants aged 18 years and above, or BMI ≥ 99%
(percentile) per Centers for Disease Control and Prevention growth charts for participants
> 12 and < 18 years of age (no BMI exclusion for participants ≤ 12 years of age).
A known clinical diagnosis of diabetes or pre-diabetes, or a history of insulin dependency
within 3 months of screening.
Average daily percent time with hyperglycemia ≥ 5% of the monitored screening continuous
glucose monitoring (CGM) time.
Known allergy or sensitivity to RZ358 or any component of the drug.